great work all... other than those already and identified, i add:
- the confidence of PR has been noted, but, when answering the HC group question of "what is PAR's greatest threat?" his answer wasn't the product failing or falling short, it was simply PAR not complying with the requirements of FDA... he holds no fears of the quality and safety of PPS...insane in itself when entering 2 x phase III trials.. when he mentioned complying with FDA which others have failed to do, i couldn't help but think he was referencing Mesoblast of recent times...
I was a little distracted while watching and listening as i was doing work on pc at the same time.... so, i may be wrong, but, PR gave me the feeling that once TGA provisional approval application is submitted (post FDA feedback) then a yes / no answer couldn't be received quicker than what i had previously thought... perhaps i wasn't concentrating, or perhaps i took it too simplistically, but, gut feel he meant we could have a far quicker answer... anyone else get this sense?
hope to watch again once / if recording becomes available...
the podcast update from 51 capital from last night worth a listen for their thoughts...
https://fiftyonecapital.podbean.com/
(20min delay)